Logo Icon
OrthoLength Pro Clinical & Patient Community
Log in Register
MEDICAL DISCLAIMER: The information provided on OrthoLength Pro is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified orthopedic surgeon.
Fact Checked by Clinical Team Study Summary

The Impact of Type 1 Diabetes Mellitus on Growth Patterns in Saudi Children and Adolescents: A Comprehensive Guide

Al
Alqahtani YA, A Shati A, Alsha...
January 01, 2026
9 views
View on PubMed
5 min read 939 words Type 1 Diabetes growth patterns Medically Reviewed

Overview

Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune condition that affects the body's ability to produce insulin, a hormone essential for regulating blood sugar levels. The impact of T1DM on growth and development in children and adolescents has been a topic of interest for many years, with some studies suggesting that the condition may affect linear growth and increase the risk of short stature. A recent retrospective cross-sectional study conducted in Saudi Arabia aimed to assess 1 and identify factors independently associated with short stature among Saudi school-age children and adolescents with T1DM, compared to a healthy control group. This article explores evidence related to Type 1 Diabetes growth patterns.

The study's purpose was to investigate the relationship between T1DM and growth patterns in children and adolescents, with a focus on the roles of glycemic control, disease duration, and nutritional factors. The findings of this study have important implications for the management and care of children and adolescents with T1DM, highlighting the need for systematic longitudinal growth monitoring and early identification of those at highest risk of growth impairment.

Medical Background

T1DM is a complex condition that requires careful management to prevent complications and ensure optimal growth and development. The condition is characterized by the autoimmune destruction of pancreatic beta cells, leading to a deficiency in insulin production. As a result, individuals with T1DM require exogenous insulin therapy to regulate their blood sugar levels.

Glycemic control is a critical aspect of T1DM management, as poor control can lead to a range of complications, including microvascular and macrovascular disease, nephropathy, retinopathy, and neuropathy. Additionally, poor glycemic control has been linked to growth impairment and short stature in children and adolescents with T1DM.

Linear growth is a complex process that involves the coordinated action of multiple hormones, including growth hormone, insulin-like growth factor-1 (IGF-1), and thyroid hormone. In children and adolescents with T1DM, growth impairment may occur due to a range of factors, including poor glycemic control, insulin deficiency, and nutritional deficiencies.

Short stature is defined as a height below the third percentile for age and gender, and it can have significant psychological and social implications for affected individuals. In the context of T1DM, short stature may be associated with a range of factors, including disease duration, glycemic control, and nutritional status.

Key Takeaways

  • Children and adolescents with T1DM have a higher prevalence of short stature compared to their healthy peers.
  • Disease duration is a strong, independent predictor of short stature in T1DM, with progressively higher risk as disease duration lengthens.
  • Intermediate and long-standing disease duration are significant independent predictors of short stature, regardless of glycemic control status.
  • Glycemic control, vitamin D status, time in range, and treatment adherence are not significantly associated with short stature after adjustment.
  • Systematic longitudinal growth monitoring is essential for early identification and intervention in patients with T1DM, particularly those with disease duration exceeding five years.

Methodology

The study was conducted at an endocrinology clinic in Saudi Arabia and included 250 patients with T1DM aged 5-18 years, as well as 267 healthy controls. The patients with T1DM were matched to the healthy controls using propensity score matching, resulting in a final sample of 231 matched pairs.

Data were extracted from electronic medical records using a standardized form, and anthropometric measurements were converted to Z-scores and percentiles using validated Saudi growth charts. Short stature was defined as a height below the third percentile for age and gender.

Univariate and multivariable logistic regression analyses were performed to identify factors associated with short stature among T1DM participants. The results of the study provide valuable insights into the relationship between T1DM and growth patterns in children and adolescents.

Results & Complications

The study found that the median age of the T1DM participants was 13.0 years, with a slight male predominance (58.0%). The proportion of short stature was significantly higher in the T1DM group compared to the control group (6.1% vs. 1.7%, p = 0.016).

The study also found that the proportion of short stature increased progressively with diabetes duration, with 3.0% of patients with new-onset disease, 14.9% with intermediate duration (2-5 years), and 25.0% with long-standing disease (>5 years) having short stature (p = 0.001).

Age at onset of T1DM was also significantly associated with having short stature (p = 0.036). In multivariable analysis, intermediate and long-standing disease duration remained significant independent predictors of short stature, regardless of glycemic control status.

The study's findings highlight the importance of early identification and intervention in patients with T1DM, particularly those with disease duration exceeding five years. The results also underscore the need for systematic longitudinal growth monitoring and tailored management strategies to optimize growth and development in children and adolescents with T1DM.

FAQ

Q: What is the impact of T1DM on growth and development in children and adolescents?

A: T1DM can affect linear growth and increase the risk of short stature in children and adolescents, particularly those with poor glycemic control and long-standing disease duration.

Q: What are the key factors associated with short stature in T1DM?

A: Disease duration, intermediate and long-standing disease duration, and age at onset of T1DM are significant independent predictors of short stature in T1DM.

Q: How can growth impairment be prevented or managed in children and adolescents with T1DM?

A: Systematic longitudinal growth monitoring, optimized glycemic control, and tailored management strategies can help prevent or manage growth impairment in children and adolescents with T1DM.

Q: What are the psychological and social implications of short stature in children and adolescents with T1DM?

A: Short stature can have significant psychological and social implications for affected individuals, including decreased self-esteem, social withdrawal, and decreased quality of life.

More on: Type 1 Diabetes growth patterns Last reviewed: July 22, 2026

Community Disclaimer

This article reflects personal experiences and insights shared by members of the limb lengthening community. It is intended for informational and discussion purposes only, and does not constitute medical advice, diagnosis, or treatment. Individual experiences may vary. Always consult with a qualified orthopedic surgeon before making any medical decisions regarding limb lengthening procedures.

Explore Related Research

Clinical Insight

Read Full Summary →
Clinical Insight

A Comprehensive Guide to Limb Lengthening in Achondroplasia: Understanding the Costs, Benefits, and Risks

Overview Achondroplasia is a genetic disorder that affects bone growth, leading to short stature and a range of other physical and emotional challenges. Limb lengthening surgery has emerged as a viable treatment option for individuals with achondroplasia, offering the potential to increase stature and improve overall quality of life. A recent study examined the cost-effectiveness of limb lengthening in patients with 1, using a Markov model to evaluate the economic impact of the procedure on the Spanish health system. This guide will delve into the medical background of achondroplasia and limb lengthening, explain the key takeaways from the study, and provide an in-depth look at the methodology, results, and potential complications of the procedure. Medical Background Achondroplasia is the most common form of short-limbed dwarfism, affecting approximately 1 in 25,000 to 1 in 30,000 births. The condition is caused by a mutation in the FGFR3 gene, which disrupts the normal process of bone growth and development. As a result, individuals with achondroplasia often experience a range of physical challenges, including short stature, bowed legs, and joint problems. Limb lengthening surgery, also known as distraction osteogenesis, is a procedure that involves cutting and gradually lengthening the bones of the legs or arms to increase stature. The procedure typically involves the use of an external fixator, a device that is attached to the bone and slowly lengthens it over time. The process of bone lengthening is complex and requires careful monitoring and management to minimize the risk of complications. The medical term 'quality-adjusted life years' (QALYs) refers to a measure of the value of health outcomes, taking into account both the quality and quantity of life. In the context of limb lengthening surgery, QALYs are used to evaluate the effectiveness of the procedure in improving the overall health and well-being of patients with achondroplasia. The 'incremental cost-effectiveness ratio' (ICER) is a statistical measure that compares the cost of a treatment to its effectiveness, expressed in terms of QALYs gained. The ICER is an important tool for evaluating the cost-effectiveness of medical interventions and informing healthcare policy decisions. Key Takeaways The study found that patients with achondroplasia who undergo limb lengthening surgery gain an average of 5.954 QALYs more than unoperated patients. The mean incremental cost of the procedure is €49,480, resulting in an ICER of €8,310/QALY. The probabilistic sensitivity analysis (PSA) yielded a mean quality of life gain of 6.287 QALYs and a mean cost increase of €49,131, translating to an ICER of €7,814/QALY. Limb lengthening surgery in patients with achondroplasia can be considered a cost-effective intervention according to commonly accepted willingness-to-pay thresholds in Spain and other Western countries. Methodology The study employed a Markov model to evaluate the cost-effectiveness of limb lengthening surgery in patients with achondroplasia. The Markov model is a statistical tool used to simulate the progression of a disease or condition over time, taking into account various health states and transitions. In this study, the model was used to estimate the costs and health outcomes of limb lengthening surgery compared to no surgery. The model was populated with data from a range of sources, including clinical trials, observational studies, and expert opinion. The study also performed a probabilistic sensitivity analysis (PSA) to account for uncertainty in the model parameters and estimate the robustness of the results. Results & Complications The study found that limb lengthening surgery is a cost-effective intervention for patients with achondroplasia, resulting in significant gains in QALYs and improved quality of life. However, as with any surgical procedure, there are potential risks and complications associated with limb lengthening. These may include infection, nerve damage, and complications related to the use of the external fixator. Patients should be carefully evaluated and monitored before and after surgery to minimize the risk of complications and ensure the best possible outcomes. The study's findings are subject to certain limitations, including the use of a hypothetical cohort and the reliance on modeling assumptions. However, the results provide valuable insights into the cost-effectiveness of limb lengthening surgery and can inform healthcare policy decisions and clinical practice guidelines. Further research is needed to fully understand the long-term outcomes and cost-effectiveness of the procedure. FAQ What is achondroplasia, and how does it affect the body? Achondroplasia is a genetic disorder that affects bone growth, leading to short stature and a range of other physical challenges. It can cause bowed legs, joint problems, and other complications that can impact daily life and overall health. What is limb lengthening surgery, and how does it work? Limb lengthening surgery involves cutting and gradually lengthening the bones of the legs or arms to increase stature. The procedure typically involves the use of an external fixator, a device that is attached to the bone and slowly lengthens it over time. What are the potential benefits and risks of limb lengthening surgery? The potential benefits of limb lengthening surgery include significant gains in QALYs and improved quality of life. However, there are also potential risks and complications, including infection, nerve damage, and complications related to the use of the external fixator. How long does the limb lengthening process take, and what kind of follow-up care is required? The limb lengthening process typically takes several months to a year or more to complete, depending on the individual case and the extent of lengthening required. Patients will require regular follow-up care with their surgeon and other healthcare providers to monitor progress and address any complications that may arise.

Read Full Summary →
Clinical Insight

Revolutionizing Achondroplasia Treatment: Understanding Vosoritide Therapy

Overview Achondroplasia, a genetic disorder affecting bone growth, is the most common cause of short-limbed dwarfism. Traditional treatment options have focused on surgical interventions, such as limb lengthening, to improve mobility and reduce discomfort. However, these procedures can be invasive, costly, and may not address the underlying pathology. The introduction of vosoritide, a C-type natriuretic peptide analogue, has marked a significant shift in the treatment paradigm. This novel therapy targets the molecular mechanisms underlying 1, offering a potentially more effective and less invasive approach. A recent single-center cohort study has provided valuable insights into the real-world efficacy and safety of vosoritide in children with achondroplasia, including those with prior orthopedic surgeries. Medical Background Achondroplasia is a congenital disorder characterized by impaired bone growth, resulting in shortened limbs, macrocephaly, and narrowed joints. The condition is caused by mutations in the FGFR3 gene, which regulates bone growth and development. C-type natriuretic peptide (CNP) plays a crucial role in this process, promoting bone growth by inhibiting the activity of FGFR3. Vosoritide, a CNP analogue, mimics the action of natural CNP, stimulating bone growth and potentially improving the symptoms of achondroplasia. Orthopedic surgeries, such as limb lengthening, have been the primary treatment option for achondroplasia. These procedures involve the use of external fixators or internal devices to gradually lengthen the bones, often requiring multiple surgeries and prolonged recovery periods. While limb lengthening can improve mobility and reduce discomfort, it is a complex and invasive process, carrying risks of complications, such as infection, nerve damage, and joint instability. Vosoritide therapy offers a non-surgical alternative, targeting the underlying molecular mechanisms of achondroplasia. By promoting bone growth, vosoritide has the potential to improve linear and appendicular growth, reducing the need for surgical interventions and associated risks. The approval of vosoritide has generated significant interest among patients, families, and healthcare professionals, with many seeking to understand its efficacy, safety, and potential benefits. Key Takeaways Vosoritide is a C-type natriuretic peptide analogue, approved for the treatment of achondroplasia. The therapy targets the underlying molecular mechanisms of achondroplasia, promoting bone growth and potentially reducing the need for surgical interventions. A recent single-center cohort study has demonstrated the efficacy and safety of vosoritide in children with achondroplasia, including those with prior orthopedic surgeries. Mean height z-scores improved significantly, with a gain of +0.38 ± 0.45, indicating enhanced linear growth. Arm span z-scores also showed significant improvement, with a gain of +0.32 ± 0.48, suggesting increased appendicular growth. No serious treatment-related adverse events were reported, highlighting the safety profile of vosoritide therapy. Methodology The single-center cohort study included 25 children with achondroplasia, aged 2.9-14.3 years, who received vosoritide therapy for a mean duration of 12.7 months. Z-scores were calculated using an AI-assisted growth assessment tool, which has been previously validated for children with achondroplasia. The z-scores provided a standardized measure of growth, allowing for comparisons between patients and assessment of treatment response. Multiple linear regression analyses were performed to identify predictors of response, adjusting for factors such as sex, age, BMI z-scores, and surgical history. However, the study acknowledged that these analyses were likely underpowered to detect meaningful predictors, due to the relatively small sample size. Results & Complications The study demonstrated significant improvements in mean height z-scores, from -0.62 ± 1.09 to -0.24 ± 1.20 (p < .001), indicating enhanced linear growth. Arm span z-scores also showed significant improvement, from -1.28 ± 0.93 to -0.96 ± 0.91 (p = .007), suggesting increased appendicular growth. Sitting height z-scores exhibited a non-significant trend toward improvement, while BMI z-scores remained stable. A subgroup analysis of 8 patients with prior limb-lengthening surgery and 17 without surgical history showed no significant differences in treatment response. This finding suggests that vosoritide therapy may be effective in patients with and without prior surgical interventions. The study reported no serious treatment-related adverse events, highlighting the safety profile of vosoritide therapy. However, as with any medical treatment, potential risks and complications may exist, and patients should discuss these with their healthcare provider. FAQ Q: What is vosoritide, and how does it work? Vosoritide is a C-type natriuretic peptide analogue, which targets the molecular mechanisms underlying achondroplasia, promoting bone growth and potentially reducing the need for surgical interventions. Q: Is vosoritide approved for use in children with achondroplasia? Yes, vosoritide has been approved for the treatment of achondroplasia in children. Q: What are the potential benefits of vosoritide therapy? Vosoritide may enhance linear and appendicular growth, reducing the need for surgical interventions and associated risks. It may also improve mobility and reduce discomfort. Q: Are there any potential risks or complications associated with vosoritide therapy? As with any medical treatment, potential risks and complications may exist. Patients should discuss these with their healthcare provider and carefully weigh the benefits and risks of vosoritide therapy.

Read Full Summary →
Clinical Insight

A Comprehensive Guide to Humeral Lengthening in Achondroplasia: Patient Perspectives and Treatment Outcomes

OverviewAchondroplasia, a genetic disorder affecting bone growth, is the most common cause of short-limbed dwarfism. Individuals with achondroplasia often experience significant shortening of their limbs, including the upper limbs, which can impair their ability to perform daily activities independently. While lower-1 is a relatively common procedure, humeral lengthening is often delayed or not considered as a treatment option. This study aimed to evaluate the functional impact of upper-limb shortening and gather patient perspectives on humeral lengthening, with a focus on the association between treatment timing and acceptance.Medical BackgroundAchondroplasia is a congenital disorder that affects the production of cartilage, leading to shortened bones and characteristic physical features. The condition is caused by a mutation in the FGFR3 gene, which regulates bone growth and development. In individuals with achondroplasia, the upper limbs are often shorter than average, with a typical arm span that is significantly less than the height. This shortening can lead to difficulties with everyday activities, such as reaching, lifting, and performing personal care tasks.Humeral lengthening is a surgical procedure designed to increase the length of the humerus (upper arm bone) and improve the overall function of the upper limb. The procedure typically involves using an external fixator, a device that is attached to the bone and slowly lengthens it over time. The process of lengthening can take several months to a year or more, depending on the individual's condition and the desired outcome.The goal of humeral lengthening is to improve the functional ability of the upper limb, allowing individuals to perform daily activities with greater ease and independence. The procedure can also have aesthetic benefits, as it can help to improve the overall proportions of the body and enhance self-esteem.Key TakeawaysHumeral lengthening is a surgical procedure designed to increase the length of the humerus and improve upper limb function in individuals with achondroplasia.The procedure can improve daily functioning, independence, and aesthetic satisfaction in patients with achondroplasia.Earlier integration of humeral lengthening into treatment protocols may be beneficial for patients with achondroplasia.Patient perspectives on humeral lengthening are influenced by treatment timing, with earlier treatment associated with higher satisfaction and fewer regrets.Untreated adults with achondroplasia may experience persistent difficulties and regrets about not undergoing humeral lengthening earlier in life.MethodologyThis study was conducted as a single-center, cross-sectional questionnaire study, involving 27 patients with achondroplasia. The patients were divided into three groups according to their treatment status: those who had undergone humeral lengthening, those who were considering the procedure, and those who had not undergone or considered the procedure.The study used a questionnaire to collect data on the patients' demographics, medical history, and experiences with humeral lengthening. The questionnaire also assessed the patients' levels of independence in daily activities, functional and aesthetic satisfaction, and willingness to undergo humeral lengthening.The response rate for the study was 89%, with 24 patients completing the survey. The data were analyzed to identify trends and patterns in the patients' responses, with a focus on the association between treatment timing and acceptance.Results &amp; ComplicationsThe study found that patients who underwent humeral lengthening reported improved daily function and high satisfaction, with 80% of respondents indicating that they were satisfied with the outcome of the procedure. In contrast, untreated adults with achondroplasia expressed regret about not undergoing the procedure earlier in life, with 40% of respondents indicating that they had persistent difficulties with daily activities.Pediatric patients with achondroplasia generally had low satisfaction with their current level of function, but 64% of respondents expressed interest in undergoing humeral lengthening in the future. The study's findings suggest that earlier integration of humeral lengthening into treatment protocols may be beneficial for patients with achondroplasia.As with any surgical procedure, humeral lengthening carries risks and complications, including infection, nerve damage, and issues with bone healing. However, the study's findings suggest that the benefits of the procedure may outweigh the risks for many patients with achondroplasia.FAQQ: What is achondroplasia, and how does it affect the upper limbs?A: Achondroplasia is a genetic disorder that affects bone growth, leading to shortened limbs, including the upper limbs. The condition can impair independence in daily activities and cause difficulties with reaching, lifting, and performing personal care tasks.Q: What is humeral lengthening, and how does it work?A: Humeral lengthening is a surgical procedure that uses an external fixator to slowly lengthen the humerus (upper arm bone) over time. The goal of the procedure is to improve the functional ability of the upper limb and enhance aesthetic satisfaction.Q: Is humeral lengthening a safe and effective procedure?A: Like any surgical procedure, humeral lengthening carries risks and complications, including infection, nerve damage, and issues with bone healing. However, the study's findings suggest that the benefits of the procedure may outweigh the risks for many patients with achondroplasia.Q: What are the benefits of undergoing humeral lengthening earlier in life?A: The study's findings suggest that earlier integration of humeral lengthening into treatment protocols may be beneficial for patients with achondroplasia, as it can improve daily functioning, independence, and aesthetic satisfaction. Untreated adults with achondroplasia may experience persistent difficulties and regrets about not undergoing the procedure earlier in life.

Read Full Summary →